

REMARKS

Interview Summary

Applicant thanks the Examiner for the telephone interview on October 5, 2006. It was agreed during the interview that the application would be allowed if Applicant canceled claims 31, 43, 45, 46 and 47 and filed a terminal disclaimer.

35 U.S.C. § 112, first paragraph, New Matter

Claim 31 and those dependent therefrom have been rejected under 35 U.S.C. § 112, first paragraph as allegedly containing new matter.

In an effort to advance prosecution, claims 31, 43, 45, 46 and 47 have been canceled.

Amendment of the claims is made without prejudice, without intent to abandon any originally claimed subject matter, and without intent to acquiesce in any rejection of record. Applicant expressly reserves the right to file one or more continuing applications hereof containing the canceled or unamended claims.

Obviousness-Type Double Patenting


A terminal disclaimer is being filed concurrently herewith, thereby obviating the obvious-type double patenting rejection with respect to U.S. 6,638,513.

CONCLUSION

In light of the claim amendments and above remarks, Applicant submits that the present application is in condition for allowance.

Respectfully submitted,

October 9, 2006

By: 
Amy Hessler
Registration No. 50,310
(510) 923-3833

Customer No. 27476
Amy Hessler
Novartis Vaccines and Diagnostics
Intellectual Property
P.O. Box 8097
Emeryville, CA 94662-8097
Telephone: (510) 923-3833
Facsimile: (510) 655-3542